Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Experimental Medicine
Erschienen in: Clinical and Experimental Medicine 3/2019

03.05.2019 | Review Article

Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies

verfasst von: Majid Lotfinia, Meghdad Abdollahpour-Alitappeh, Behzad Hatami, Mohammad Reza Zali, Morteza Karimipoor

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Adeno-associated virus (AAV)-derived vectors are currently the most common type of viral vectors used in gene therapy clinical trials. The presence of neutralizing antibodies (NAbs) against wild-type AAVs in the host body is one of the limitations for the successful use of AAV vectors. AAV capsid manipulation, by which recombinant vectors lose their ability to interact with NAbs, can help overcome this obstacle. Various methods can be used for this purpose, including directed evolution as well as conjugation of certain chemical groups to AAV epitopes. The present review concisely explains the use of AAV vectors in the clinic for gene therapy of some diseases, their limitations, and solutions to these limitations.
Literatur
1.
2.
Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science (80-) [Internet]. 2018;359.
3.
Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. United States. 1965;149:754–6.
4.
Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology. United States. 2004;330:375–83.CrossRef
5.
Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. United States. 1983;45:555–64.
6.
Becerra SP, Koczot F, Fabisch P, Rose JA. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol. United States. 1988;62:2745–54.
7.
Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol. United States. 2000;74:2777–85.
8.
Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. United States. 2008;21:583–93.CrossRef
9.
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. England. 2011;12:341–55.CrossRef
10.
Samulski RJ, Muzyczka N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol. United States. 2014;1:427–51.CrossRef
11.
Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. United States. 2011;365:2357–65.CrossRef
12.
Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. United States. 2014;371:1994–2004.CrossRef
13.
Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood [Internet]. 2004;103:1253–60.CrossRefPubMed
14.
Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol. United States. 2004;78:3110–22.
15.
Wang L, Bell P, Lin J, Calcedo R, Tarantal AF, Wilson JM. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol Ther. United States. 2011;19:2012–20.CrossRef
16.
Bell P, Gao G, Haskins ME, et al. Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum Gene Ther. United States. 2011;22:985–97.CrossRef
17.
Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood. United States. 2009;113:3682–9.
18.
Calcedo R, Morizono H, Wang L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. United States. 2011;18:1586–8.CrossRef
19.
Murphy SL, Li H, Mingozzi F, et al. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J Med Virol. United States. 2009;81:65–74.CrossRef
20.
High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol. United States. 2011;807:429–57.CrossRef
21.
Zinn E, Pacouret S, Khaychuk V, et al. In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. Cell Rep [Internet]. 2015;12:1056–68.CrossRefPubMedPubMedCentral
22.
Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol. United States. 2005;79:9933–44.
23.
Ghosh A, Duan D. Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev. England. 2007;24:165–77.CrossRef
24.
Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A. 1982;79:2077–81.CrossRefPubMedPubMedCentral
25.
Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol. United States. 1984;51:611–9.
26.
Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab [Internet]. 2003;80:148–58.CrossRefPubMed
27.
Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest [Internet]. 2009;119:2388–98.CrossRefPubMedPubMedCentral
28.
Suzuki M, Bertin TK, Rogers GL, et al. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther [Internet]. 2013;21:796–805.
29.
Hosel M, Broxtermann M, Janicki H, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology [Internet]. 2012;55:287–97.CrossRefPubMed
30.
Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med [Internet]. 2006;12:342–7.CrossRefPubMed
31.
Kotterman MA, Chalberg TW, Schaffer DV. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Annu Rev Biomed Eng. United States. 2015;17:63–89.CrossRef
32.
Tseng YS, Agbandje-McKenna M. Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors. Front Immunol [Internet]. 2014;5:9.PubMedPubMedCentral
33.
Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol [Internet]. 2006;24:198–204.CrossRefPubMed
34.
Le HT, Yu QC, Wilson JM, Croyle MA. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release [Internet]. 2005;108:161–77.CrossRefPubMed
35.
Carlisle RC, Benjamin R, Briggs SS, et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med [Internet]. 2008;10:400–11.CrossRefPubMed
36.
37.
Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther [Internet]. 2005;12:107–17.CrossRefPubMed
38.
Gurda BL, Raupp C, Popa-Wagner R, et al. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J Virol [Internet]. 2012;86:7739–51.CrossRefPubMedPubMedCentral
39.
Wilson DS, Keefe AD. Random mutagenesis by PCR. Curr Protoc Mol Biol [Internet]. 2001;Chapter 8:Unit8 3.
40.
Coco WM, Levinson WE, Crist MJ, et al. DNA shuffling method for generating highly recombined genes and evolved enzymes. Nat Biotechnol [Internet]. 2001;19:354–9.CrossRefPubMed
41.
Lee GK, Maheshri N, Kaspar B, Schaffer DV. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng [Internet]. 2005;92:24–34.CrossRefPubMed
42.
Jang J-H, Schaffer DV, Shea LD. Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther. United States. 2011;19:1407–15.CrossRef
43.
Bartel M, Schaffer D, Buning H. Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol. Switzerland; 2011;2:204.
44.
Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther [Internet]. 2005;11:66–79.CrossRefPubMed
45.
Hauck B, Xu RR, Xie J, et al. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. Hum Gene Ther. United States. 2006;17:46–54.CrossRef
46.
Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol [Internet]. 2000;74:1761–6.CrossRefPubMedPubMedCentral
47.
Harbison CE, Weichert WS, Gurda BL, Chiorini JA, Agbandje-McKenna M, Parrish CR. Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5. J Gen Virol [Internet]. 2012;93:347–55.CrossRefPubMedPubMedCentral
48.
Gurda BL, DiMattia MA, Miller EB, et al. Capsid antibodies to different adeno-associated virus serotypes bind common regions. J Virol [Internet]. 2013;87:9111–24.CrossRefPubMedPubMedCentral
49.
Lochrie MA, Tatsuno GP, Christie B, et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol [Internet]. 2006;80:821–34.CrossRefPubMedPubMedCentral
50.
Mingozzi F, Chen Y, Murphy SL, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther [Internet]. 2012;20:1410–6.CrossRefPubMedPubMedCentral
51.
Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. United States. 2016;351:407–11.
52.
Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. United States. 2016;34:334–8.CrossRef
Metadaten
Titel
Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies
verfasst von
Majid Lotfinia
Meghdad Abdollahpour-Alitappeh
Behzad Hatami
Mohammad Reza Zali
Morteza Karimipoor
Publikationsdatum
03.05.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 3/2019
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00557-8

Weitere Artikel der Ausgabe 3/2019

Clinical and Experimental Medicine 3/2019 Zur Ausgabe

Original Article

TNF-β +252 A>G (rs909253) polymorphism is independently associated with presence of autoantibodies in rheumatoid arthritis patients

Original Article

Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients

Original Article

Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker

Original Article

Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case–control study

Original Article

Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study

Original Article

Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise